Expert M.D. addresses PBMs role, influence on ‘Top Docs Radio’
Madelaine H. Feldman, M.D., FACR – a rheumatologist with The Rheumatology Group in New Orleans and the president of the Coalition of State Rheumatology Organizations (CSRO) – discusses the role of pharmacy benefit managers (PBMs) and the power they wield in today’s health care system on the latest episode of the Medical Association of Georgia’s (MAG) ‘Top Docs Radio’ show.
Dr. Feldman addresses…
– The role of PBMs
– How PBMs fit into the prescription drug delivery system
– How PBMs have become some powerful in the health care system
– What role PBMs and drug manufacturers play in setting prescription drug costs
– PBMs rebate systems and “price concessions”
– The “Accumulator Adjustment Program” and how it affects patients
– PBMs regulatory oversight
– How the “PBM problem” can be fixed at the state and federal levels
– The steps that patients and physicians can take to make a difference
In addition to her role with CSRO, Dr. Feldman is the chair of the Alliance for Safe Biologic Medicine and the founder and past president of the Rheumatology Alliance of Louisiana. A clinical assistant professor of medicine at the Tulane University School of Medicine, Dr. Feldman is active in the advocacy arena – and she lectures to a wide array of stakeholders at the local, state and national levels. Dr. Feldman has been honored with the Tulane Medical School’s Distinguished Service Award, she was named one of the ‘Top Women in New Orleans’ by City Business in 2017, and she has been on the ‘Top Doctors’ list in New Orleans for more than 15 years. It is also worth noting that Dr. Feldman is a former radio talk show host.
Between downloads and live listeners, MAG’s ‘Top Docs Radio’ show has now reached more than 340,000 listeners and viewers – which includes people in all 50 states and more than 80 countries. The program is supported with a grant from the Alliant Health Group in memory of Tom Williams, its former CEO.
PBM Watch website
The prescription drug supply chain black box: How it works and why you should care, American Health Policy Institute
Drug Channel Institute
Removing ERISA’s Impediment to State Health Reform
Commercially-insured patients pay undiscounted list prices for one in five brand prescriptions, accounting for half of out-of-pocket spending on brand medicines